Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino... see more

Current News (NDAQ:ACAD)

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Business Wire 10 days ago

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Business Wire December 18, 2025

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Business Wire December 12, 2025

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Business Wire November 20, 2025

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Business Wire November 5, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire November 1, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 31, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 30, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

ACCESS Newswire October 29, 2025
View More News ››

Opinion & Analysis (NDAQ:ACAD)

Embrace low-cap biotech for high gains: Eden Rahim of Next Edge Capital

The Life Sciences Report March 2, 2016

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

The Calandra Report: Watch this hot tub!

Thom Calandra January 10, 2014
View More Opinion ››

Bullboard Posts (NDAQ:ACAD)

ACADIA PHARMACEUTICALS: WHAT’S NEXT AFTER THE NEGATIVE FDA A

$ACAD Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central...
AviseAnalytics - June 22, 2022

FDA Approves ACADIA Pharmaceuticals - Parkinson's Disease

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative...
DaveInCalgary - April 30, 2016

RE:RE: Long Term Hold?

Their PD product, pimavanserin, is on an expedited path to an NDA filing and their balance sheet is looking good. Great potential. Very...
captcanuck - August 9, 2013

RE: Long Term Hold?

That's a heavy blow to have discover the product is no better than what is already out there, or more importantly no different. If...
amy89 - June 21, 2008

RE: Long Term Hold?

Although it has the ability to tap into the aging baby-boomers market, it has to get to the market first. Its schizophrenia drug had...
gossipgirl - June 20, 2008

RE: Long Term Hold?

For long term, i would def. consider this stock a buy! Like you mentioned, the baby boom era def. benefits this company I also like that...
vforvalue - June 20, 2008
View more Bullboard ››

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic ...
View More »

Podcasts